PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Bezlotuxumab - Clostridioides difficile
PAD Profile : Bezlotuxumab - Clostridioides difficile
Keywords :
c.diff, antitoxin, human monoclonal antitoxin antibody
Brand Names Include :
Zinplava
Traffic Light Status
Status 1 of 1.
Status :
Non Formulary
Important
Formulations :
- Not Specified
Important Information :
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed with NICE recommendation not to use bezlotoxumab to prevent recurrence of C. Difficile infection because it is not cost effective. Bezlotoxumab will be given a NON-FORMULARY traffic light status for this indication.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Wet age-related macular degeneration
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Diabetic retinopathy
- Osteoarthritis
- Constipation
- Hepatic encephalopathy
- Travellers diarrhoea
- Penile rehabilitation
- Erectile dysfunction
- Cytomegalovirus
- Hyperuricaemia and Gout
- Vitreomacular traction
- Central retinal vein occlusion
- Peripheral arterial disease
- Dysphagia
- Diabetic macular oedema
- Diarrhoea
- Haemorrhoids
- Heart failure
- Oedema
- Lipid modification
- Haemophilia
- Cataracts
- Branch retinal vein occlusion
- Low sexual desire in menopausal women
- Hypertension
- Hypertension
- Hypertension
- Bacterial infection
- Inflammatory bowel disease
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Myopic choroidal neovascularisation
- Cystic fibrosis
- Fungal infection
- Duchenne muscular dystrophy
- Cystic fibrosis
- Hepatitis C
- Tuberculosis
- Hepatitis C
- Multiple sclerosis
- Tuberculosis
- Hepatitis C
- Hepatitis C
- Hepatitis C
- Haemophilia
- Cystic fibrosis
- Hepatitis C
- Systemic Lupus Erythematosus
- Hepatitis C
- Inclusion body myositis
- Cytomegalovirus
- Haemophilia
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Hepatitis C
- Haemophilia
- Systemic Lupus Erythematosus
- Haemophilia
- Haemophilia
- Haemophilia
- Haemophilia
- Multiple sclerosis
- Hepatitis B
- Haemophilia
- Short bowel syndrome
- Haemophilia
- Any paediatric use
- von Willebrand deficiency
- Haemophilia
- Haemophilia
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Mental Health disorders
- Mental Health disorders
- Inflammatory bowel disease
- Acne
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Non-acne dermatological indications
- Anticoagulation reversal
- Restless Leg Syndrome
- von Willebrand deficiency
- Immune thrombocytopenia
- Wet age-related macular degeneration
- Bacterial skin and skin structure infections
- Narcolepsy
- Bacterial lung infection (non-cystic fibrosis)
- Lipid modification
- Menopausal disorders
- All
- Raynaud's Phenomenon
- Atopic dermatitis
- Psoriasis
- Covid-19
- Covid-19
- Covid-19
- Inflammatory bowel disease
- Growth failure - children
- Inflammatory bowel disease
- Diabetic macular oedema
- Wet age-related macular degeneration
- Diabetic macular oedema
- Migraine (prevention)
- Urinary incontinence
- Immune thrombocytopenia
- Glaucoma / ocular hypertension
- Dry eyes
- Cancer
- Diarrhoea
- Inflammatory bowel disease
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
- Erectile dysfunction
- Parkinson's disease
- Myasthenia gravis
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Tuberculosis
- Tuberculosis
- Tuberculosis
- Covid-19
- Inflammatory bowel disease
- Rehydration in short bowel syndrome
- Faecal impaction (adults)
- Faecal impaction (children)
- Minor digestive complaints
- Haemorrhoids
- Haemorrhoids
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nausea and vomiting
- Agitation in mania and psychotic disorders
- Schizophrenia
- Intraoperative mydriasis / prevention of miosis
- Stoma
- Arrhythmias
- Acute coronary syndrome
- Acute coronary syndrome
- Inotropic support
- IV catheter maintenance
- Cardiopulmonary resuscitation
- Hepatitis D
- Hypertension (severe / crisis)
- Heart failure
- Oedema
- Hypotension
- Tissue glue / suture support
- Diagnosis of Brugada syndrome
- Heparin induced thrombocytopenia
- HIV infection
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Smoking cessation
- Endometriosis
- Surgical diagnostic
- Ocular surgery
- Chronic Obstructive Pulmonary Disease (COPD)
- Growth failure - adults
- Growth failure - children
- Oesophagitis (inducing remission)
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 November 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed with NICE recommendation not to use bezlotoxumab to prevent recurrence of C. Difficile infection because it is not cost effective.
Bezlotoxumab will be given a NON-FORMULARY traffic light status for this indication.
Associated BNF Codes
05. Infections
05.01.07. Some other antibacterials